LSV Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

LSV Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.5M	Sell	881,700 -3,100	-0.4%	-$170K	0.09%	237
2026 Q1	$50M	Buy	884,800 +2,600	+0.3%	+$152K	0.11%	218
2025 Q4	$52.4M	Buy	882,200 +36,700	+4%	+$2M	0.11%	213
2025 Q3	$45.8M	Buy	845,500 +812,284	+2,445%	+$46.5M	0.1%	217
2025 Q2	$1.83M	Buy	+33,216	New	+$1.96M	﹤0.01%	565

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AIM

ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

EHI

Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

LSV Asset Management's BMRN Position: Q2 2026 in Review

LSV Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.35% in Q2 2026, selling an estimated $170K and leaving 881,700 shares worth $50.5M. The position accounts for 0.09% of the portfolio, ranked #237.

LSV Asset Management first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $52.4M in Q4 2025. 272 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

LSV Asset Management held 881,700 shares of BioMarin Pharmaceuticals worth $50.5M as of Q2 2026.
LSV Asset Management sold 3,100 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $170K.
BioMarin Pharmaceuticals made up 0.09% of LSV Asset Management's portfolio in Q2 2026, its #237 holding.
LSV Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
LSV Asset Management's BioMarin Pharmaceuticals position peaked at $52.4M in Q4 2025.
272 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.